All Perspectives

Managing Partner Marci Eisenstein was quoted on how she works to challenge potential exclusionary factors like implicit bias that can undercut diverse attorneys’ opportunities to build large books of business.

Administrative deference – in essence, that courts resolve close questions in favor of “expert” agencies – is a cornerstone of environmental practice and we’ve blogged frequently on this issue. Courts question agencies, however, when their decisions do not square with cited evidence.

Schiff Hardin LLP is pleased to announce it has been recognized as a top law firm for women by Law360’s 2018 Glass Ceiling Report, which ranks firms based on their percentage of nonpartners and total partners who are women.

Managing Partner Marci Eisenstein was quoted on what successful gender equality in the legal industry looks like to her.

On May 24, New York Partner Tope Yusuf spoke with Thomson Reuters as part of the Next Gen Leadership: Advancing Lawyers of Color initiative.

On May 20, 2018, Secretary of the Treasury Steven Mnuchin stated that the US was “putting the trade war on hold,” pending negotiations with China to reduce the US trade deficit and address certain acts, policies, and practices related to intellectual property rights.

Susan Bart and Brian Janowsky were quoted on the dos and don’ts for pet estate planning to ensure pets are cared for when owners are no longer able.

The Trump Administration did an about-face over the weekend, announcing that the sweeping 25 percent tariffs on products imported from China were placed on hold, as the two countries try to iron out a deal that would avoid the impending trade war.

South Carolina has become the first state to enact an insurance data security act based on the Insurance Data Security Model Law drafted by the National Association of Insurance Commissioners, which is based on New York’s Cybersecurity Regulations (23 N.Y.C.R.R. Part 500).

Following a tweet from President Donald Trump that there was “big news coming soon” for the automotive industry, the Department of Commerce (DOC) formally announced on May 24, 2018 an investigation into the impact of certain automotive imports on US national security interests.

Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel explained why some biosimilar companies engaged in Biologics Price Competition and Innovation Act (BPCIA) litigation may choose to settle.

Streamlining environmental reviews and permitting for infrastructure projects is a major objective of President Trump.

LOS ANGELES, CA — Craig Gelfound, head of Arent Fox LLP’s Intellectual Property practice in Los Angeles, has once again been honored by the Daily Journal as one of the Top Intellectual Property Lawyers in California, with 2018 marking his eighth consecutive year of this recognition.

On May 17, 2018, CMS issued a strongly-worded letter to Part D plan sponsors stating that pharmacy “gag clauses” are unacceptable.

The May 21 notice provides guidance on the manner in which imports whose exclusion requests are approved by the DOC should be entered in order to avoid the Section 232 duties.

On May 21, 2018, the United States Supreme Court clarified that class action waivers in employment arbitration agreements are enforceable under the Federal Arbitration Act, as set forth in the decision of three consolidated cases.

In a recent decision, the US Court of Appeals for the Ninth Circuit held that a surgical center lacked standing to bring ERISA claims against a health plan because the plan had a valid anti-assignment provision.

Schiff Hardin has been named to the BTI Brand Elite 2018, which ranks the law firms with the best brand standing among general counsel and top legal decision makers.

Schiff Hardin has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category.

DSC Partners LLC, represented by Arent Fox, closed on a $100 million purchase of a downtown office building in Washington, DC.

Hatch-Waxman and Biosimilars Practice Group Leader Sailesh Patel was featured on the ongoing Biologics Price Competition and Innovation Act (BPCIA) Litigation he is watching.

Following delays and much build up, the White House and the Department of Health and Human Services (HHS) have released their plan to address rising pharmaceutical prices and out-of-pocket costs directly impacting patients.

A New Jersey-based company, Aromaflage, and its owners have agreed to settle charges brought by the Federal Trade Commission (FTC) regarding the company’s sale of sprays and candles that claim to be insect-repelling.

Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly examines how current Hatch-Waxman legal proceedings can be applied to Biologics Price Competition and Innovation Act (BPCIA) litigation.

Following the Presidential Proclamations issued April 30, 2018 regarding the imposition of double-digit tariffs on certain steel and aluminum imports (Section 232 tariffs), US Customs and Border Protection published further guidance detailing the implementation of the Section 232 tariffs.